Download
castellsague1.pdf 105,55KB
WeightNameValue
1000 Titel
  • Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany
1000 Autor/in
  1. Castellsague, Jordi |
  2. Perez‐Gutthann, Susana |
  3. Calingaert, Brian |
  4. Bui, Christine |
  5. Varas‐Lorenzo, Cristina |
  6. Arana, Alejandro |
  7. Prados‐Torres, Alexandra |
  8. Poblador‐Plou, Beatriz |
  9. Gonzalez‐Rubio, Francisca |
  10. Giner‐Soriano, Maria |
  11. Roso‐Llorach, Albert |
  12. Linder, Marie |
  13. Citarella, Anna |
  14. Scholle, Oliver |
  15. Blenk, Tilo |
  16. Garbe, Edeltraut |
1000 Erscheinungsjahr 2017
1000 LeibnizOpen
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2017-01-30
1000 Erschienen in
1000 Quellenangabe
  • 26(6): 615-624
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2017
1000 Lizenz
1000 Verlagsversion
  • http://dx.doi.org/10.1002/pds.4167 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484386/ |
1000 Ergänzendes Material
  • http://onlinelibrary.wiley.com/doi/10.1002/pds.4167/full#footer-support-info |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • PURPOSE: To describe the characteristics of new users of cilostazol in Europe with the aim to support the evaluation of its benefit/risk as used in regular clinical practice before the implementation of labeling changes recommended by the European Medicines Agency. METHODS: New users of cilostazol were identified in populations enrolled in five European health automated databases in the UK (The Health Improvement Network [THIN]), Spain (EpiChron cohort and Information System for the Improvement of Research in Primary Care [SIDIAP]), Sweden (National Registers), and Germany (German Pharmacoepidemiological Research Database [GePaRD]) between 2002 and 2012. New users were characterized according to the prevalence of cardiovascular disease and other comorbidities, concurrent use of interacting medications, new contraindications, duration of use, and potential off‐label prescribing. RESULTS: We identified 22 593 new users of cilostazol. The median age was between 68.0 (THIN) and 73.7 (Sweden) years. More than 78% of users had concomitant cardiovascular disease, and between 78.8% (GePaRD) and 91.6% (THIN) were treated with interacting medications. Prevalence of new cardiovascular contraindications ranged from 1.5% (THIN) to 11.6% (GePaRD), and concurrent use of two or more antiplatelet drugs ranged from 6.3% (SIDIAP) to 13.5% (EpiChron cohort). Between 39.4% (Sweden) and 52.9% (THIN) of users discontinued cilostazol in the first 3 months. Between 41.0% (SIDIAP) and 93.4% (THIN) were considered to have received cilostazol according to the European Medicines Agency labeling. CONCLUSIONS: In this collaborative European study, most cilostazol users were elderly patients with a high prevalence of cardiovascular diseases and other comorbidity and concurrent use of interacting drugs, indicating that this is a vulnerable population at high risk of complications, especially cardiovascular events.
1000 Sacherschließung
lokal pharmacoepidemiology
lokal database study
lokal cilostazol
lokal drug utilization study
lokal intermittent claudication
lokal peripheral artery disease
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/creator/Q2FzdGVsbHNhZ3VlLCBKb3JkaQ==|https://frl.publisso.de/adhoc/creator/UGVyZXrigJBHdXR0aGFubiwgU3VzYW5h|https://frl.publisso.de/adhoc/creator/Q2FsaW5nYWVydCwgQnJpYW4=|https://frl.publisso.de/adhoc/creator/QnVpLCBDaHJpc3RpbmU=|https://frl.publisso.de/adhoc/creator/VmFyYXPigJBMb3JlbnpvLCBDcmlzdGluYQ==|https://frl.publisso.de/adhoc/creator/QXJhbmEsIEFsZWphbmRybw==|https://frl.publisso.de/adhoc/creator/UHJhZG9z4oCQVG9ycmVzLCBBbGV4YW5kcmE=|https://frl.publisso.de/adhoc/creator/UG9ibGFkb3LigJBQbG91LCBCZWF0cml6|https://frl.publisso.de/adhoc/creator/R29uemFsZXrigJBSdWJpbywgRnJhbmNpc2Nh|https://frl.publisso.de/adhoc/creator/R2luZXLigJBTb3JpYW5vLCBNYXJpYQ==|https://frl.publisso.de/adhoc/creator/Um9zb_KAkExsb3JhY2gsIEFsYmVydA==|https://frl.publisso.de/adhoc/creator/TGluZGVyLCBNYXJpZQ==|https://frl.publisso.de/adhoc/creator/Q2l0YXJlbGxhLCBBbm5h|https://frl.publisso.de/adhoc/creator/U2Nob2xsZSwgT2xpdmVy|https://frl.publisso.de/adhoc/creator/QmxlbmssIFRpbG8=|https://frl.publisso.de/adhoc/creator/R2FyYmUsIEVkZWx0cmF1dA==
1000 Label
1000 Förderer
  1. Otsuka Pharmaceutical Europe Ltd |
  2. Gallions, Wexham Springs Framewood Road, Wexham SL3 6PJ, UK |
1000 Fördernummer
  1. -
  2. -
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Otsuka Pharmaceutical Europe Ltd |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Gallions, Wexham Springs Framewood Road, Wexham SL3 6PJ, UK |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6404717.rdf
1000 Erstellt am 2017-09-27T10:27:21.424+0200
1000 Erstellt von 122
1000 beschreibt frl:6404717
1000 Bearbeitet von 288
1000 Zuletzt bearbeitet Thu Apr 08 09:09:49 CEST 2021
1000 Objekt bearb. Thu Apr 08 09:09:49 CEST 2021
1000 Vgl. frl:6404717
1000 Oai Id
  1. oai:frl.publisso.de:frl:6404717 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source